Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Fondazione Italiana Linfomi - ETS: Clinical Trials & FDA Approval Profile

Fondazione Italiana Linfomi - ETS (Global / Institutional) sponsors 20 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (7 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)25.0%
Median Closed Enrollment vs National (145 pts)22 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Fondazione Italiana Linfomi - ETS
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)20
Active Pipeline (Recruiting Now)13 (7)
Completed vs Stopped Early1 / 5 (25.0%)
Median Closed Actual Enrollment22 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Fondazione Italiana Linfomi - ETS
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06492837Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma PatientsPhase IIACTIVE NOT RECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Fondazione Italiana Linfomi - ETS Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI